Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & PrecautionsAdditional Info
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Clarinex

[Desloratadine]

Drug Interactions

In two controlled crossover clinical pharmacology studies in healthy male (n= 12 in each study) and female (n= 12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.

In 3 separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n= 18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n= 18) or with cimetidine 600 mg every 12 hours for 14 days (n= 18) under steady state conditions to normal healthy male and female volunteers.

Text Continues Below



Although increased plasma concentrations (Cmax and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed (see Table 1), there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.


Table 1
Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers

Desloratadine 3-Hydroxydesloratadine
AUC AUC Cmax 0-24 hrs Cmax 0-24 hrs

Erythromycin (500 mg Q8h) +24% +14% +43% +40%
Ketoconazole (200 mg Q12h) +45% +39% +43% +72%
Azithromycin (500 mg day 1, 250 mg QD x 4 days) +15% +5% +15% +4%
Fluoxetine (20 mg QD) +15% +0% +17% +13%
Cimetidine (600 mg Q12h) +12% +19% -11% -3%

Pharmacodynamics:

Wheal and Flare:

Human histamine skin wheal studies following single and repeated 5 mg doses of desloratadine have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal tachyphy-laxis within the desloratadine 5 mg group over the 28 day treatment period. The clinical relevance of histamine wheal skin testing is unknown.

Page:  << Prev | 1 | 2 | 3 | 4 | 5 | Next >>







New Features

New ADHD Site!


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service